109054 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides against enzymes
DOUBLE STRANDED RNA AND USES THEREOF
#902NEOANTIGENS CREATED BY ABERRANT-INDUCED SPLICING AND USES THEREOF IN ENHANCING IMMUNOTHERAPY
#903COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
#904PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION
#905IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS
#906Compositions and methods for reactivating latent immunodeficiency virus
#907TARGETING EGLN1 IN CANCER
#908RNA INTERFERENCE COMPOSITIONS AND METHODS FOR MALIGNANT TUMORS
#909MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES
#910SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
#911ANTISENSE OLIGONUCLEOTIDES FOR ALLELE SPECIFICITY
#912ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENT
#913COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING AMYOTROPHIC LATERAL SCLEROSIS
#914APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES
#915COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
#916METHODS FOR TREATING PARKINSON'S DISEASE
#917Treatment Of Sepsis With PCSK9 And LDLR Modulators
#918TALEN-BASED AND CRISPR/CAS-BASED GENE EDITING FOR BRUTON'S TYROSINE KINASE
#919USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER
#920CONTROL OF INSECT INFESTATION
#921RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
#922RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#923MIRNA FOR USE IN THERAPY
#924COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES
#925RNA INTERFERENCE AGENTS FOR GST-PI GENE MODULATION
#926Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
#927ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#928LIPID COMPOSITIONS
#929NEUROFILAMENT PROTEIN FOR GUIDING THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS
#930MODULATION OF SPTLC1 VIA RECOMBINANT ADENO-ASSOCIATED VECTORS
#931RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITING EXPRESSION OF DYSTROPHIA MYOTONICA PROTEIN KINASE AND/OR INTERFERING WITH A TRINUCLEOTIDE REPEAT EXPANSION IN THE 3' UNTRANSLATED REGION OF THE DMPK GENE
#932PRODUCTS AND COMPOSITIONS
#933Antisense oligomers targeting PCSK9
#934Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same
#935CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#936gRNA targeting HPK1 and a method for editing HPK1 gene
#937RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#938METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERS
#939THERAPEUTIC GENE EDITING FOR ELANE-ASSOCIATED DISEASE
#940METHOD FOR PREVENTING ORAL CANCER
#941METHOD TO OBTAIN LOW TRITERPENE/TRITERPENOID-CONTAINING NATURAL RUBBER LATEX
#942RNAI INDUCED REDUCTION OF ATAXIN-3 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3
#943Cell line with METTL3 gene knocked out, its construction method and interference vector
#944POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF
#945COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
#946Methods of Treating Influenza A Virus Infections
#947Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
#948COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
#949Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
#950Genetically modified mesenchymal stem cells for use in cardiovascular prosthetics
#951Extended dicer substrate agents and methods for the specific inhibition of gene expression
#952POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
#953COMPOSITIONS AND METHODS FOR MODULATING EGG DEVELOPMENT IN MOSQUITOES
#954Extended dicer substrate agents and methods for the specific inhibition of gene expression
#955Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
#956RNA DRUGS AND METHOD OF TREATING AGE-RELATED DISEASE
#95717ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof
#958Compositions and methods for inhibiting ALDH2 expression
#959Methods and compositions for treatment of cholesteryl ester storage disease
#960METHODS OF INHIBITING PROLIFERATIVE CELLS
#961PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
#962COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
#963USE OF TNKS INHIBITORS FOR REGENERATION OF CARTILAGE
#964Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
#965PHARMACOPROTEOMICS PLATFORM IDENTIFYING KINOME FEATURES REGULATING DRUG RESPONSE IN CANCER
#966Compositions and methods for treating beta-hemoglobinopathies
#967Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
#968IMMUNOTHERAPY OF CANCER
#969DONOR T-CELLS WITH KILL SWITCH
#970Fibrotic treatment
#971Methods for reducing LRRK2 expression
#972Modulators of CAS9 polypeptides and methods of use thereof
#973Compositions and methods to restore paternal UBE3A gene expression in human Angelman syndrome
#974KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#975PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF MUTANT GARS PROTEIN
#976COMPOSITIONS AND METHODS FOR SEQUESTERING VIRUSES
#977Compositions and methods for treating endometriosis
#978SILENCING TGF-BETA 1 and COX2 USING siRNAs DELIVERED in a POLYPEPTIDE NANOPARTICLE ALONE and in COMBINATION with IMMUNE CHECKPOINT INHIBITORS to TREAT CANCER
#979MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING HYPERTROPHIC CARDIOMYOPATHY
#980MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING CENTRONUCLEAR MYOPATHY
#981ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
#982METHODS AND COMPOSITIONS FOR INCREASING THE SUPPRESSIVE FUNCTION OF REGULATORY T-CELLS (TREGS)
#983USE OF AKT INHIBITORS IN OPHTHALMOLOGY
#984Means and method for producing and purifying viral vectors
#985Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide
#986POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF
#987MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE
#988HAEMATOPOIETIC STEM CELL-GENE THERAPY FOR WISKOTT-ALDRICH SYNDROME
#989PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING
#990Methods and pharmaceutical compositions for treating lymphoid malignancy
#991PARN AS A BIOMARKER AND THERAPEUTIC TARGET
#992Short hairpin RNA (shRNA734) and use of same to positively select and eliminate genetically modified cells
#993Substituted imidazoles for preventing and/or treating cell or tissue necrosis
#994MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#995MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
#996Preparation and use of sugar-targeting nanoparticles for modifying SiRNA
#997RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
#998Compositions and methods of treating muscle dystrophy
#999Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
#1000COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES
#1001Compositions and methods for regulating body weight and metabolic syndromes
#1002Inhibition of protein kinases to treat Friedreich ataxia
#1003Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1004MATRIX METALLOPROTEINASE-1 ANTISENSE OLIGONUCLEOTIDES
#1005Peptides for use as cell-penetrating peptides
#1006AMINE CATIONIC LIPIDS AND USES THEREOF
#1007PDE3B VARIANTS
#1008Methods for treating hypercholesterolemia
#1009Methods of treating cholangiocarcinoma
#1010Methods and compositions for treating asthma and allergic diseases
#1011Targeting microRNA-101-3p in cancer therapy
#1012Compositions and methods for modulating PKK expression
#1013Compound usable as cationic lipid
#1014PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK
#1015Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
#1016COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY AND TREATING RNA DOMINANCE DISORDERS
#1017USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
#1018Compounds and methods for the modulation of proteins
#1019Lipid formulations for nucleic acid delivery
#1020COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES
#1021Inhibition of oxidative stress in atrial fibrillation
#1022PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE OR CACHEXIA COMPRISING, AS ACTIVE INGREDIENT, miRNA LOCATED IN DLK1-DIO3 CLUSTER OR VARIANT THEREOF
#1023ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
#1024CONJUGATED LIPOMERS AND USES THEREOF
#1025TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND DISORDERS ASSOCIATED WITH THE SPINAL CORD
#1026TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1027Nanometric pharmaceutical composition in the form of liposomes or nanoemulsion containing specific sequences of interference RNA
#1028INHIBITION OF CATALYTIC SITE COMMON TO MULTIPLE 3 ALPHA-OXIDOREDUCTASES FOR TREATMENT OF PROSTATE CANCER
#1029Protein Kinase RNA-Like Endoplasmic Reticulum Kinase (PERK) Inhibitors for Prevention and/or Treatment of Lung Injury and/or Inflammation
#1030MATERIALS AND METHODS FOR MODULATING INTRAOCULAR AND INTRACRANIAL PRESSURE
#1031RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
#1032Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1033VECTOR PRODUCTION IN SERUM FREE MEDIA
#1034GUAYULE WITH INCREASED RUBBER PRODUCTION AND YIELD
#1035SHORT INTERFERING RNA TARGETING VARIANT C1858T OF GENE PTPN22
#1036PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
#1037Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity
#1038Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
#1039Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
#1040MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#1041THERAPEUTIC AGENT FOR CARTILAGE-RELATED DISEASE
#1042POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF
#1043Methods for treating cancers
#1044Muscle targeting complexes and uses thereof for treating myotonic dystrophy
#1045NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY
#1046Cytotoxic fluoropyrimidine polymers and methods of use thereof
#1047METHODS AND COMPOSITIONS FOR MODULATING MYELOPEROXIDASE (MPO) EXPRESSION
#1048GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS TARGETING GANGLIOSIDE BIOSYNTHETIC PATHWAYS
#1049Compositions and methods for treating pancreatitis
#1050METHODS OF ACTIVATING CELLS VIA PTP 1B INHIBITION
#1051ANTIBACTERIAL PHAGE, THERAPEUTIC COMPOSITION, BACTERICIDAL AGENT, FOOD, BACTERIA IDENTIFICATION KIT, THERAPEUTIC COMPOSITION MANUFACTURING METHOD, BACTERIA ELIMINATION METHOD, BACTERIA IDENTIFICATION METHOD, AND ANIMAL THERAPEUTIC METHOD
#1052Inhibition of NGLY1 for the treatment of cancer
#1053TEMPERATURE CONTROLLED DNA POLYMERASE INHIBITORS
#1054Methods of treating cancer and/or enhancing sensitivity to cancer treatment by increasing tumor mutation burden or tumor indels
#1055RNA targeting of mutations via suppressor tRNAs and deaminases
#1056Compositions and methods for treating eye disorders
#1057Agents for improved delivery of nucleic acids to eukaryotic cells
#1058Method of allele specific silencing for the treatment of autosomal dominant Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
#1059Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
#1060Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same
#1061NOVEL LINKER, PREPARATION METHOD, AND APPLICATION THEREOF
#1062Methods of treating cancers
#1063Methods for production of MSC-derived exosomes
#1064STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES
#1065Therapeutic inhibition of lactate dehydrogenase and agents therefor
#1066ARGINASE SUPPRESSION FOR CANCER TREATMENT
#1067Compositions and methods for predicting response and resistance to CDK4/6 inhibition
#1068Compositions and methods for use in controlling mosquito-borne viruses
#1069METHODS OF TREATING CANCER
#1070METHODS AND AGENTS FOR ENHANCING T CELL THERAPIES
#1071Glucokinase (GCK) iRNA compositions and methods of use thereof
#1072Antisense nucleic acid targeting PCSK9
#1073COMPOSITIONS AND METHODS FOR INHIBITING THE PRODUCTION OR ACTIVITY OF D-2HYDROXYGLUTARATE IN SUBJECTS AFFLICTED WITH CANCER
#1074Modulation of factor 11 expression
#1075Methods of treating VEGF/VEGFR resistant prostate, renal, or colorectal cancers using combination therapies
#1076Allele-specific silencing therapy for dynamin 2-related diseases
#1077TMPRSS6 iRNA compositions and methods of use thereof
#1078METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#1079Compositions and methods for treating facioscapulohumeral dystrophy
#1080Methods of inhibiting formation of alpha synuclein aggregates
#1081Modulation of gene expression and screening for deregulated protein expression
#1082Modulators of EZH2 expression
#1083OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION
#1084REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
#1085Methods and compositions related to T-cell activity
#1086FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING
#1087Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
#1088Methods and compositions for reducing immunosuppression by tumor cells
#1089Antisense oligonucleotides useful in treatment of Pompe disease
#1090RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
#1091Method to synthesize a biodegradable dextran for agent delivery
#1092NOVEL KINASE FOR TREATING AND PREVENTING FUNGAL INFECTIONS, AND USE THEREOF
#1093METHODS OF GENE THERAPY
#1094DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
#1095METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASE OR DISORDER
#1096Mammalian cells for producing a secreted protein
#1097Methods for treating and diagnosing prostate cancer
#1098METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
#1099Ferrochelatase inhibitors and methods of use
#1100MUCOSAL HEALING PROMOTER
#1101Products and Methods for Treatment of Familial Amyotrophic Lateral Sclerosis
#1102TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT
#1103OLIGONUCLEOTIDE DERIVATIVE OR SALT THEREOF
#1104Compositions and methods for delivery of biomacromolecule agents
#1105Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate
#1106Aminoalcohol lipidoids and uses thereof
#1107MULTICISTRONIC EXPRESSION CONSTRUCTS
#1108Use of MIR101 or MIR128 in the treatment of seizure disorders
#1109Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
#1110Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Reduction
#1111Compounds and methods for reducing FXI expression
#1112COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#1113INHIBITION OF ZSCAN4 FOR INHIBITION OF TUMOR GROWTH
#1114Modulators of PNPLA3 expression
#1115Modulators of PCSK9 expression
#1116Vesicles comprising a PTEN inhibitor and uses of same
#1117Hexameric tetrahedral RNA nanostructures
#1118Methods and compositions for inhibiting expression of LDHA
#1119Interfering RNA molecules
#1120Compositions and methods for inhibiting GYS2 expression
#1121Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#1122Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1123Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
#1124METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER
#1125Compositions Comprising Immune System Activators and Method of Using Same
#1126Combination vectors and methods for treating cancer
#1127INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF
#1128Method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor
#1129Method of targeting senescent cells
#1130Composition for suppressing inflammation
#1131Oligonucleotide therapy for Wilson disease
#1132Peptides and nanoparticles for intracellular delivery of molecules
#1133Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
#1134Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA
#1135METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION
#1136Gene therapeutics for treating bone disorders
#1137METHOD OF DIAGNOSIS, PROGNOSIS OR TREATMENT OF NEURODEGENERATIVE DISEASES
#1138Reelin antibodies for treatment of atherosclerosis
#1139REDUCING CUTANEOUS SCAR FORMATION AND TREATING SKIN CONDITIONS
#1140Methods and compositions for the activation of gamma-delta T-cells
#1141PREVENTION OR TREATMENT OF CHRONIC ORGAN INJURY
#1142COMPOSITIONS AND METHODS FOR TREATING CANCER
#1143Gene therapy of the FAAH pseudogene
#1144Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
#1145DNMT3B GENE-DEFICIENT CHO CELL LINE, PREPARATION AND APPLICATIONS THEREOF AND RECOMBINANT PROTEIN EXPRESSION SYSTEM USING THE SAME
#1146Methods of treating cancer by inhibiting SETD2
#1147COMPOSITIONS AND METHODS FOR TREATING GRAVES DISEASE
#1148Method of synthesis of an ionizable cationic lipid
#1149MODULATION OF HSD17B13 EXPRESSION
#1150Methods and pharmaceutical compositions for treating tubulin carboxypeptidases associated diseases
#1151P38 map kinase inhibitors
#1152METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS
#1153ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#1154COMPOSITIONS AND METHODS FOR TREATING CANCER
#1155PREVENTION AND TREATMENT OF ORGAN FIBROSIS
#1156TMPRSS6 iRNA compositions and methods of use thereof
#1157MODULATORS OF DNM2 EXPRESSION
#1158Conjugated antisense compounds and their use
#1159Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
#1160Oligomeric compounds comprising bicyclic nucleotides and uses thereof
#1161Hexokinase 2-specific inhibitors for use in acute central nervous system injury
#1162Methods of treating wounds using cathepsin K inhibitors
#1163H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9
#1164DELIVERING CRISPR THERAPEUTICS WITH LIPID NANOPARTICLES
#1165Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
#1166SHIP INHIBITION TO COMBAT OBESITY
#1167NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS
#1168CELL PROLIFERATION INHIBITOR AND CANCER TREATMENT OR PREVENTION PHARMACEUTICAL COMPOSITION INCLUDING CELL PROLIFERATION INHIBITOR
#1169Fibrotic treatment
#1170Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#1171Compositions for modulating SOD-1 expression
#1172HSD17B13 variants and uses thereof
#1173COMPOSITIONS AND METHODS FOR TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS
#1174Oligonucleotides for inducing paternal UBE3A expression
#1175Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
#1176COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1177Treatment for skeletal diseases caused by intracellular protein trafficking defects
#1178Methods of polynucleotide preparation using multivalent cation salt compositions
#1179DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof
#1180METHOD FOR ENHANCING RECOVERY OF COSMETIC LASER-TREATED SKIN
#1181RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)
#1182ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS
#1183Dual Targeting siRNA Agents
#1184PD-1 related cancer therapy
#1185Amphoteric liposomes comprising imino lipids
#1186Adeno-associated virus virion for gene transfer to nervous system cells
#1187PARP9 and PARP14 as key regulators of macrophage activation
#1188ANTISENSE-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
#1189Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#1190Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
#1191Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
#1192CRISPR-related methods and compositions with governing gRNAS
#1193Dynamin 2 inhibitor for the treatment of centronuclear myopathies
#1194Methods of treating bone loss
#1195NUCLEIC ACID MOLECULES THAT CONFER RESISTANCE TO COLEOPTERAN PESTS
#1196Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof
#1197Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
#1198Methods for the treatment of Leber congenital amaurosis
#1199Methods and compositions for diagnosing and treating diseases
#1200Compositions for treating heart disease by inhibiting the action of mAKAPβ